To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
A phase 1/2 trial of Disitamab vedotin in bladder & urothelial cancer, run by RemeGen Co., Ltd., now recruiting.
Overview
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 is a phase 1/2 interventional study registered as NCT06378242 by RemeGen Co., Ltd., with 24 participants planned, started 2024-06-14 and due to reach its primary completion in 2029-03-15. Interventions recorded: Disitamab Vedotin for injection.
Similar pages
not linked directly; found by shared links- TrialDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Shares RemeGen, Disitamab vedotin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Shares Disitamab vedotin, Bladder & urothelial cancer and the tag pipeline.
- TrialDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialEfficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialNeoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Shares RemeGen, Disitamab vedotin and the tag pipeline.